SMITHKLINE BEECHAM's KYTRIL PURCHASED BY 70% OF TARGET HOSPITALS, COMPANY SAYS; TAGAMET IS RETAINING 40% MARKET SHARE 24 WEEKS POST-PATENT EXPIRATION
Executive Summary
SmithKline Beecham's Kytril (granisetron) has been purchased by 70% of hospitals targeted by the company, SB Pharmaceuticals North America President Jerry Karabelas reported at the Bear Steams Seventh Annual Health Care Conference in New York City Sept. 22.